{"id":457298,"date":"2021-03-15T07:03:19","date_gmt":"2021-03-15T11:03:19","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=457298"},"modified":"2021-03-15T07:03:19","modified_gmt":"2021-03-15T11:03:19","slug":"matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2020-financial-and-operational-results-on-march-29-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2020-financial-and-operational-results-on-march-29-2021\/","title":{"rendered":"Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial and Operational Results on March 29, 2021"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">BEDMINSTER, N.J., March  15, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_0EeOaISQ3hNAEPCTcvQiprS-NcZUNII6M5uLjIlhg-N4Yfi_SMaujlcVC2KzWnd20BVUNOCI5eyx_RMTPSeClbtSy9rMg-bH3wpttcKzVXxVigsS3vRdpF6i-ar2FFe\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Matinas BioPharma Holdings, Inc.<\/a> (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company\u00a0focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, today announced that the Company will host a conference call and live audio webcast on Monday, March 29, 2020 at 8:00 a.m. ET to discuss operational and financial results for the fourth quarter and full year ended December 31, 2020.<\/p>\n<p align=\"justify\">To participate in the call, please dial (877) 407-5976 (Toll-Free) or (412) 902-0031 (Toll). The live webcast will be accessible on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nCvLGtFf8w0D2spO8N_ppiQeYHPj5gd_DKbU07HRvaL5BbRnJktfQHdalg7TLsHSquyRJNv7TrudbxUDxqYotGLGsdUrOCno8gWh49C3TZ0=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Investors<\/a>\u00a0section of Matinas\u2019 website, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mnrXc7tOXwBbLVis43JiNYz4FFB2lTaZK1X6U7IxpcBgHLAe_RJs5iiKsLPzRw440SPpmZqdHDRsRiqLqNRrHAtLpMJ92EjpWzI9Fa5e9-c=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.matinasbiopharma.com<\/a>, and archived for 90 days.<\/p>\n<p align=\"justify\">\n        <strong>About Matinas BioPharma<\/strong>\n      <\/p>\n<p align=\"justify\">Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care for patients in areas of significant unmet medical need. Company leadership has a deep history and knowledge of drug development and is supported by a world-class team of scientific advisors.<\/p>\n<p align=\"justify\">LYPDISO, the Company\u2019s lead product candidate for the treatment of cardiovascular and metabolic conditions, is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia.<\/p>\n<p align=\"justify\">In addition, Matinas is developing a portfolio of products based upon its proprietary lipid nanocrystal (LNC) drug delivery platform, which can solve complex challenges relating to the safe and effective delivery of potent medicines, making them orally bioavailable, less toxic, and targeted to cells and tissues.<\/p>\n<p align=\"justify\">MAT2203 is an oral, encochleated formulation of the well-known, but highly toxic, antifungal medicine amphotericin B, primarily used to treat serious invasive fungal infections. MAT2203 is currently in a Phase 2 open-label, sequential cohort study (EnACT) in HIV-infected patients with cryptococcal meningitis. EnACT is currently enrolling patients in its second cohort, with the next DSMB evaluation of safety and efficacy data anticipated to occur in the middle of 2021.<\/p>\n<p align=\"justify\">MAT2501 is an oral, encochleated formulation of the broad-spectrum aminoglycoside antibiotic medicine amikacin, primarily used to treat chronic and acute bacterial infections. The Company has been awarded up to $3.75 million from the Cystic Fibrosis Foundation (CFF) to support development of MAT2501 toward an indication to treat nontuberculous mycobacterial (NTM) lung disease, including infections in patients with cystic fibrosis (CF)..\u00a0<\/p>\n<p align=\"justify\">\n        <strong>Forward Looking Statements<\/strong>:<\/p>\n<p align=\"justify\">This release contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the ENHANCE-IT study, the Company\u2019s strategic focus and the future development of its product candidates, including MAT9001, the anticipated timing of regulatory submissions, the anticipated timing of clinical studies, the anticipated timing of regulatory interactions, the Company\u2019s ability to identify and pursue development and partnership opportunities for its products or platform delivery technology on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;could,&#8221; &#8220;believes,&#8221; &#8220;estimates&#8221; and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company\u2019s intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company\u2019s products; and the other factors listed under &#8220;Risk Factors&#8221; in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma\u2019s product candidates are all in a development stage and are not available for sale or use.<\/p>\n<p align=\"justify\">\n        <strong>Investor and Media Contact<\/strong>\n      <\/p>\n<p align=\"justify\">Peter Vozzo<br \/>Westwicke\/ICR<br \/>443-213-0505<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4Zwh3TIURdSD5QKirVuaKZqYaiDJE_7CUQ32aWHzFgDsCt5Xam6CyvyxfsSkSr1Tj2C6p4N3IhXvBvzfAYiFIXAQtYOLLXqvjfIZoqUnMAw=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">peter.vozzo@westwicke.com<\/a><\/p>\n<p align=\"justify\">Source: Matinas BioPharma Holdings, Inc.<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTczMSM0MDYzMzA1IzIwMjM2MTg=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/7142c119-8e3f-415c-8f83-347e6087bb5a\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BEDMINSTER, N.J., March 15, 2021 (GLOBE NEWSWIRE) &#8212; Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company\u00a0focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, today announced that the Company will host a conference call and live audio webcast on Monday, March 29, 2020 at 8:00 a.m. ET to discuss operational and financial results for the fourth quarter and full year ended December 31, 2020. To participate in the call, please dial (877) 407-5976 (Toll-Free) or (412) 902-0031 (Toll). The live webcast will be accessible on the Investors\u00a0section of Matinas\u2019 website, www.matinasbiopharma.com, and archived for 90 days. About Matinas BioPharma Matinas BioPharma is a clinical-stage biopharmaceutical company focused on &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2020-financial-and-operational-results-on-march-29-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial and Operational Results on March 29, 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-457298","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial and Operational Results on March 29, 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2020-financial-and-operational-results-on-march-29-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial and Operational Results on March 29, 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BEDMINSTER, N.J., March 15, 2021 (GLOBE NEWSWIRE) &#8212; Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company\u00a0focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, today announced that the Company will host a conference call and live audio webcast on Monday, March 29, 2020 at 8:00 a.m. ET to discuss operational and financial results for the fourth quarter and full year ended December 31, 2020. To participate in the call, please dial (877) 407-5976 (Toll-Free) or (412) 902-0031 (Toll). The live webcast will be accessible on the Investors\u00a0section of Matinas\u2019 website, www.matinasbiopharma.com, and archived for 90 days. About Matinas BioPharma Matinas BioPharma is a clinical-stage biopharmaceutical company focused on &hellip; Continue reading &quot;Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial and Operational Results on March 29, 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2020-financial-and-operational-results-on-march-29-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-15T11:03:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTczMSM0MDYzMzA1IzIwMjM2MTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2020-financial-and-operational-results-on-march-29-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2020-financial-and-operational-results-on-march-29-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial and Operational Results on March 29, 2021\",\"datePublished\":\"2021-03-15T11:03:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2020-financial-and-operational-results-on-march-29-2021\\\/\"},\"wordCount\":785,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2020-financial-and-operational-results-on-march-29-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4OTczMSM0MDYzMzA1IzIwMjM2MTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2020-financial-and-operational-results-on-march-29-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2020-financial-and-operational-results-on-march-29-2021\\\/\",\"name\":\"Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial and Operational Results on March 29, 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2020-financial-and-operational-results-on-march-29-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2020-financial-and-operational-results-on-march-29-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4OTczMSM0MDYzMzA1IzIwMjM2MTg=\",\"datePublished\":\"2021-03-15T11:03:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2020-financial-and-operational-results-on-march-29-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2020-financial-and-operational-results-on-march-29-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2020-financial-and-operational-results-on-march-29-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4OTczMSM0MDYzMzA1IzIwMjM2MTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4OTczMSM0MDYzMzA1IzIwMjM2MTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2020-financial-and-operational-results-on-march-29-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial and Operational Results on March 29, 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial and Operational Results on March 29, 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2020-financial-and-operational-results-on-march-29-2021\/","og_locale":"en_US","og_type":"article","og_title":"Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial and Operational Results on March 29, 2021 - Market Newsdesk","og_description":"BEDMINSTER, N.J., March 15, 2021 (GLOBE NEWSWIRE) &#8212; Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company\u00a0focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, today announced that the Company will host a conference call and live audio webcast on Monday, March 29, 2020 at 8:00 a.m. ET to discuss operational and financial results for the fourth quarter and full year ended December 31, 2020. To participate in the call, please dial (877) 407-5976 (Toll-Free) or (412) 902-0031 (Toll). The live webcast will be accessible on the Investors\u00a0section of Matinas\u2019 website, www.matinasbiopharma.com, and archived for 90 days. About Matinas BioPharma Matinas BioPharma is a clinical-stage biopharmaceutical company focused on &hellip; Continue reading \"Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial and Operational Results on March 29, 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2020-financial-and-operational-results-on-march-29-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-15T11:03:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTczMSM0MDYzMzA1IzIwMjM2MTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2020-financial-and-operational-results-on-march-29-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2020-financial-and-operational-results-on-march-29-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial and Operational Results on March 29, 2021","datePublished":"2021-03-15T11:03:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2020-financial-and-operational-results-on-march-29-2021\/"},"wordCount":785,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2020-financial-and-operational-results-on-march-29-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTczMSM0MDYzMzA1IzIwMjM2MTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2020-financial-and-operational-results-on-march-29-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2020-financial-and-operational-results-on-march-29-2021\/","name":"Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial and Operational Results on March 29, 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2020-financial-and-operational-results-on-march-29-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2020-financial-and-operational-results-on-march-29-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTczMSM0MDYzMzA1IzIwMjM2MTg=","datePublished":"2021-03-15T11:03:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2020-financial-and-operational-results-on-march-29-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2020-financial-and-operational-results-on-march-29-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2020-financial-and-operational-results-on-march-29-2021\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTczMSM0MDYzMzA1IzIwMjM2MTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTczMSM0MDYzMzA1IzIwMjM2MTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/matinas-biopharma-to-webcast-conference-call-discussing-fourth-quarter-and-full-year-2020-financial-and-operational-results-on-march-29-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial and Operational Results on March 29, 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/457298","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=457298"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/457298\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=457298"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=457298"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=457298"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}